Trodelvy (sacituzumab govitecan) for the Treatment of Advanced Triple-Negative Breast Cancer

Trodelvy (sacituzumab govitecan-hziy) is the first and the only FDA-approved antibody-drug conjugate to treat metastatic triple-negative breast cancer (TNBC) in adult patients. Credit: Bioconjugator.



  • Trodelvy
  • Trodelvy
  • Trodelvy